Safety and Effectiveness of Ruxolitinib for Treatment of Myeloproliferative Neoplasm: A Meta-Analysis / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 493-501, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-690960
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of ruxolitinib in treatment of myeloproliferative neoplasm.</p><p><b>METHODS</b>Random clinical trials (~September 30, 2017) were identified from PubMed, Embase, Cochrane Library, Clinical Trials, CBM and Chinese Journal Full-text Database. The quality of RCT was assessed by Cochrane risk bias. Meta analysis was performed with Revman 5.3.</p><p><b>RESULTS</b>Ruxolitinib was efficacious in relieving splenomegaly (RR 49.12, 95% CI [15.81-152.59], P<0.001). The incidence of anemia significantly increased after ruxolitinib treatment (RR 1.71, 95% CI [1.05-2.77], P=0.16), while the thrombocytopenia (RR 1.04, 95% CI [0.50-2.16], P=0.92) and neutropenia (RR 2.46, 95% CI [0.91-6.61], P=0.07) had no statistical difference as compared with that in control group. Ischemia events had no significant difference as compared with control (RR 0.57, 95% CI [0.33-1.00], P=0.05). Infection events had no significant difference as compared with the control group (RR 1.18, 95% CI [0.79-1.78], P=0.24).</p><p><b>CONCLUSION</b>Ruxolitinib is an efficacious therapeutic strategy on MPD with controlling splenomegaly. However,anemia events and bleeding events may threat its clinical safety, so more high quality RCT are needed.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pyrazoles
/
Thrombocytopenia
/
Myeloproliferative Disorders
/
Neoplasms
Type of study:
Systematic reviews
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS